Stock YPH ASTELLAS PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Astellas Pharma Inc. Deutsche Boerse AG

Equities

YPH

JP3942400007

Pharmaceuticals

Market Closed - Deutsche Boerse AG
Other stock markets
 01:11:05 29/06/2024 am IST 		5-day change 1st Jan Change
9.016 EUR -0.68% Intraday chart for Astellas Pharma Inc. +2.88% -17.89%
03/06 US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab MT
31/05 U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.? Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date CI

Valuation

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Capitalization 1 31,05,395 31,61,421 35,19,738 33,81,409 29,46,773 28,51,074 - -
Enterprise Value (EV) 1 27,77,545 28,29,733 32,03,752 30,04,569 26,11,086 33,65,667 32,40,418 27,45,730
P/E ratio 16 x 26.2 x 28.5 x 34.7 x 173 x 38.9 x 19.2 x 1,996 x
Yield 2.39% 2.47% 2.62% 3.19% 4.26% 4.71% 5% 0.06%
Capitalization / Revenue 2.39 x 2.53 x 2.72 x 2.23 x 1.84 x 1.7 x 1.62 x 1.53 x
EV / Revenue 2.14 x 2.26 x 2.47 x 1.98 x 1.63 x 2.01 x 1.84 x 1.47 x
EV / EBITDA 8.95 x 13.6 x 13.6 x 12.6 x 14.2 x 11.2 x 8.36 x 7.26 x
EV / FCF -16.6 x 10.3 x 14.1 x 10.3 x -3.88 x 12.2 x 12.1 x 11 x
FCF Yield -6.04% 9.73% 7.08% 9.7% -25.8% 8.23% 8.27% 9.05%
Price to Book 2.41 x 2.28 x 2.39 x 2.24 x 1.85 x 1.9 x 1.87 x 1.98 x
Nbr of stocks (in thousands) 18,58,405 18,57,474 18,41,831 17,95,756 17,92,986 17,93,128 - -
Reference price 2 1,671 1,702 1,911 1,883 1,644 1,590 1,590 1,590
Announcement Date 14/05/20 27/04/21 27/04/22 27/04/23 25/04/24 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Net sales 1 13,00,843 12,49,528 12,96,163 15,18,619 16,03,672 16,74,100 17,61,153 18,65,158
EBITDA 1 3,10,387 2,08,703 2,35,370 2,38,767 1,83,358 2,99,736 3,87,830 3,78,356
EBIT 1 2,43,991 1,36,051 1,55,686 1,33,029 25,518 1,26,667 2,14,518 2,10,025
Operating Margin 18.76% 10.89% 12.01% 8.76% 1.59% 7.57% 12.18% 11.26%
Earnings before Tax (EBT) 1 2,45,350 1,45,324 1,56,886 1,32,361 24,969 99,307 1,95,209 2,69,271
Net income 1 1,95,411 1,20,589 1,24,086 98,714 17,045 73,228 1,48,189 1,42,797
Net margin 15.02% 9.65% 9.57% 6.5% 1.06% 4.37% 8.41% 7.66%
EPS 2 104.2 64.93 67.08 54.24 9.510 0.2462 0.7266 0.7965
Free Cash Flow 1 -1,67,795 2,75,459 2,26,705 2,91,326 -6,73,327 2,76,987 2,68,019 2,48,559
FCF margin -12.9% 22.05% 17.49% 19.18% -41.99% 16.55% 15.22% 13.33%
FCF Conversion (EBITDA) - 131.99% 96.32% 122.01% - 92.41% 69.11% 65.69%
FCF Conversion (Net income) - 228.43% 182.7% 295.12% - 378.25% 180.86% 174.06%
Dividend per Share 2 40.00 42.00 50.00 60.00 70.00 74.87 79.56 0.9500
Announcement Date 14/05/20 27/04/21 27/04/22 27/04/23 25/04/24 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2020 S2 2021 S1 2021 S2 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2 2025 Q1 2025 Q2 2025 S1 2025 Q3 2025 Q4 2025 S2 2026 Q1 2026 S1 2026 S2 2027 S1
Net sales 1 - 6,15,480 - 6,51,666 3,40,627 3,03,870 - 3,81,791 3,80,394 7,62,185 4,02,180 3,54,254 3,74,990 3,92,148 7,67,138 4,21,932 4,14,602 - 4,09,469 4,26,700 8,14,224 4,43,793 3,95,939 - - - - -
EBITDA 1 - - - - - - - - - - - - - - - 70,087 42 - 89,100 81,600 - 1,13,400 9,300 - - - - -
EBIT 1 - 86,872 - 90,169 79,202 -13,685 - 33,147 86,744 1,19,891 61,388 -48,250 45,794 5,222 51,016 23,103 -48,601 - 39,895 47,538 1,01,294 61,917 -13,858 - - - - -
Operating Margin - 14.11% - 13.84% 23.25% -4.5% - 8.68% 22.8% 15.73% 15.26% -13.62% 12.21% 1.33% 6.65% 5.48% -11.72% - 9.74% 11.14% 12.44% 13.95% -3.5% - - - - -
Earnings before Tax (EBT) 1 - 89,091 - 89,085 78,317 -10,516 - 31,679 88,801 1,20,480 59,758 -47,877 46,850 5,328 52,178 21,452 -48,661 - 33,814 39,822 64,944 53,621 -15,772 - - - - -
Net income 1 - 72,838 - 71,609 60,886 -8,409 - 24,812 71,622 96,434 48,405 -46,125 33,129 -1,459 31,670 18,653 -33,278 - 26,199 31,033 49,478 41,787 -12,009 - - - - -
Net margin - 11.83% - 10.99% 17.87% -2.77% - 6.5% 18.83% 12.65% 12.04% -13.02% 8.83% -0.37% 4.13% 4.42% -8.03% - 6.4% 7.27% 6.08% 9.42% -3.03% - - - - -
EPS 2 - 39.21 - 38.65 32.86 -4.430 - 13.59 39.28 52.87 26.56 -25.19 18.46 -0.8000 17.66 10.40 -18.55 - 9.885 14.12 33.40 20.20 -19.31 - - - - -
Dividend per Share 20.00 21.00 21.00 25.00 - - 25.00 - - 30.00 - - - 35.00 35.00 - 35.00 35.00 - - 37.00 - - 37.00 - 39.00 39.00 41.00
Announcement Date 14/05/20 30/10/20 27/04/21 29/10/21 02/02/22 27/04/22 27/04/22 01/08/22 31/10/22 31/10/22 06/02/23 27/04/23 01/08/23 01/11/23 01/11/23 05/02/24 25/04/24 25/04/24 - - - - - - - - - -
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Net Debt 1 - - - - - 5,14,594 3,89,344 -
Net Cash position 1 3,27,850 3,31,688 3,15,986 3,76,840 3,35,687 - - 1,05,344
Leverage (Debt/EBITDA) - - - - - 1.717 x 1.004 x -
Free Cash Flow 1 -1,67,795 2,75,459 2,26,705 2,91,326 -6,73,327 2,76,987 2,68,019 2,48,559
ROE (net income / shareholders' equity) 15.3% 9% 8.7% 6.7% 1.1% 5.61% 10.1% 12%
ROA (Net income/ Total Assets) 11.6% 6.33% 6.81% 5.53% 3.28% 3.65% 6.24% 6.24%
Assets 1 16,78,858 19,05,121 18,21,523 17,85,770 5,19,665 20,05,015 23,74,250 22,86,946
Book Value Per Share 2 694.0 748.0 799.0 839.0 890.0 835.0 817.0 802.0
Cash Flow per Share 2 140.0 104.0 110.0 112.0 97.50 1.690 1.920 1.910
Capex 1 41,267 31,384 30,739 36,441 38,056 60,500 54,700 50,500
Capex / Sales 3.17% 2.51% 2.37% 2.4% 2.37% 3.61% 3.11% 2.71%
Announcement Date 14/05/20 27/04/21 27/04/22 27/04/23 25/04/24 - - -
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Astellas Pharma Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
1,590 JPY
Average target price
1,855 JPY
Spread / Average Target
+16.69%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 815B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 314B
ABBVIE INC. Stock AbbVie Inc.
+10.68% 303B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.57% 242B
ROCHE HOLDING AG Stock Roche Holding AG
+2.04% 224B
NOVARTIS AG Stock Novartis AG
+13.31% 218B
AMGEN INC. Stock Amgen Inc.
+8.48% 168B
PFIZER, INC. Stock Pfizer, Inc.
-2.81% 159B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4503 Stock
  4. YPH Stock
  5. Financials Astellas Pharma Inc.